On Friday 24 June, the European Commission granted Valneva a conditional marketing authorisation for its adjuvanted inactivated whole virus SARS-CoV-2 vaccine (VLA2001).
The authorisation, valid for one year and renewable, was formally granted by the European Commission following the positive recommendation of the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) on 23 June (see EUROPE 12979/25). The licence was issued for use in 18-50 year olds.
This is the sixth vaccine against SARS-CoV-2 to be licenced in the European Union.
At the time of writing, only one SARS-CoV-2 vaccine was a candidate for conditional marketing authorisation. It is Vidprevtyn developed by Sanofi Pasteur.
Three vaccines against SARS-CoV-2 have been accepted by the EMA for continued evaluation: - Sputnik V, developed by the Gamaleya Institute; - the Covid-19 HIPRA vaccine (PHH-1V), developed by HIPRA Human Health S.L.U.; - the Vero Cell inactivated SARS-CoV-2 vaccine, developed by Sinovac. These vaccines do not currently qualify for marketing authorisation.
Link to the summary of the marketing authorisation for Valneva vaccine: https://aeur.eu/f/2cj (Original version in French by Émilie Vanderhulst)